OTC-PINK:EVFM

Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO

Retrieved on: 
Thursday, April 18, 2024
FDA, Patient, Lactic acid, Orange, Pregnancy, Woman, OTCQB, Hormone, Orange Book, Citric acid, Birth, Patent, SAN, Birth control

SAN DIEGO, April 18, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that the United States Patent and Trademark Office (USPTO) issued to the Company a Notice of Allowance for patent application 17/823,020 entitled, "Compositions and Methods for Enhancing the Efficacy of Contraceptive Microbicides." This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.

Key Points: 
  • This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.
  • The allowed claims cover methods of contraception with a composition that encompasses Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel.
  • The patent, when issued, will be Evofem's fifth patent for Phexxi in the United States.
  • "This patent allowance attests to the innovation Phexxi brings to contraception and a woman's ability to protect herself from unintended pregnancy with no hormones."

Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023

Retrieved on: 
Wednesday, March 27, 2024
Constitutional right, SAN, Research, Prior authorization, Acquisition, Lactic acid, Patient, Pregnancy, Fourth, Woman, Note, Security, WAC, OTCQB, Marketing, Citric acid, Medi-Cal, Beauty salon

SAN DIEGO, March 27, 2024 /PRNewswire/ -- The company behind Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2023. Highlights include:

Key Points: 
  • Highlights include:
    Delivered $18.2 million of Phexxi net product sales in 2023, an impressive increase compared to 2022 given the 73% reduction in field force and absence of growth capital in 2023.
  • Sales and marketing expense was 64% of net sales for 2023, a key milestone for the Company and a significant improvement from prior years.
  • For the year ended December 31, 2023, net product sales were $18.2 million compared to $16.8 million in net product sales in the prior year.
  • For the three months ended December 31, 2023, net product sales were $4.8 million compared to $0.2 million in the prior year period.

Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal

Retrieved on: 
Wednesday, March 20, 2024
California Department, Hormone, SAN, Lactic acid, Prescription, Medicaid, OTCQB, FDA, Citric acid, Medi-Cal, Birth control

SAN DIEGO, March 20, 2024 /PRNewswire/ -- Commercial-stage women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFMD) today announced that it has successfully renegotiated the rebate for Phexxi® (lactic acid, citric acid and potassium bitartrate), its hormone-free, woman-controlled contraceptive, with Medi-Cal, the California state Medicaid program.

Key Points: 
  • Phexxi is the first and only locally-acting contraceptive gel approved by the FDA.
  • It is applied zero-to-60 minutes before intercourse and works, without hormones, by maintaining the natural vaginal biome with a pH that is naturally inhospitable to sperm.
  • The renegotiated rebate improves Evofem's rebate on Medi-Cal prescriptions by 7.4%, while affording price protection to Medi-Cal against future Phexxi WAC increases.
  • Medi-Cal beneficiaries may receive one box of 12 single-use Phexxi applicators per dispensing, and up to three boxes in any 75-day period.

For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy

Retrieved on: 
Thursday, March 7, 2024
Diabetes, OTCQB, Woman, Citric acid, Obesity, FDA, Pregnancy, FACOG, Lactic acid, Patient, Birth, Prescription, Birth control

SAN DIEGO, March 7, 2024 /PRNewswire/ -- Use of GLP-1 receptor agonists, or GLP-1s, is skyrocketing in the United States, with more than nine million prescriptions for Ozempic, Wegovy, Mounjaro, and similar diabetes and obesity drugs written during the last three months of 2022 alone.1 Zepbound weekly prescriptions hit 25,000 in December 2023, just one month after it was approved to treat obesity.2 These drugs may make oral birth control pills less effective at certain points in the dosing schedule, making an unintended pregnancy more likely.

Key Points: 
  • This highlights the critical need for a non-systemic, non-hormonal method, like Phexxi, to prevent unintended pregnancy."
  • Users of oral birth control considering GLP-1 treatment are encouraged to plan ahead to prevent unintended pregnancy.
  • Having a contraceptive strategy in place and the right product at your fingertips enables spontaneous intimacy no matter where you are in your GLP-1 dosing schedule.
  • An on-demand, hormone-free method is a logical choice to provide these patients additional protection they need.

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023

Retrieved on: 
Thursday, February 1, 2024
SAN, Growth, Citric acid, Lactic acid, OTCQB, Marketing

SAN DIEGO, Feb. 1, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced strong preliminary, unaudited results for fiscal 2023, including record net sales of Phexxi® (lactic acid, citric acid, and potassium bitartrate), its hormone-free contraceptive gel, and the Company's lowest total operating expenses since becoming a commercial stage company in 2020.

Key Points: 
  • SAN DIEGO, Feb. 1, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced strong preliminary, unaudited results for fiscal 2023, including record net sales of Phexxi® (lactic acid, citric acid, and potassium bitartrate) , its hormone-free contraceptive gel, and the Company's lowest total operating expenses since becoming a commercial stage company in 2020.
  • Achieved preliminary net product sales in the range of $18.1 to $18.3 million in 2023, an impressive increase compared to 2022 given the 73% reduction in field force and absence of growth capital in 2023.
  • Company reached a key milestone with net product sales higher than sales and marketing expense for 2023.
  • Evofem expects to report full results for the three- and twelve-month periods ended December 31, 2023, in mid-March 2024.

Washington State HCA Removes Prior Authorization for Hormone-Free "In the Moment" Contraceptive PHEXXI Ahead of Huskies vs. Wolverines Championship Game

Retrieved on: 
Monday, January 8, 2024
Fee, HCA, Pregnancy, Lactic acid, Woman, Texas Longhorns, FDA, Hormone, Sugar Bowl, Sugar, Testosterone, OTCQB, Michigan Wolverines, Citric acid, Medicaid, Birth, Prior authorization, Birth control

SAN DIEGO, Jan. 8, 2024 /PRNewswire/ -- Multiple studies have shown that testosterone levels surge in men watching a favorite sports team compete. A major victory – like the Washington Huskies over the Texas Longhorns in the Sugar Bowl last week – can result in a 20 percent increase in testosterone for fans of the winning team. The hormone spike and overall thrill of victory can give rise to intimate celebrations requiring in-the-moment contraception to prevent unintended pregnancy.

Key Points: 
  • The hormone spike and overall thrill of victory can give rise to intimate celebrations requiring in-the-moment contraception to prevent unintended pregnancy.
  • Phexxi is the first and only locally-acting contraceptive gel approved by the FDA.
  • The improved coverage makes it that much easier for women on the state HCA's Managed Medicaid and Fee for Service Medicaid plans to get Phexxi.
  • Phexxi continues to be included on the Washington State HCA Preferred Drug List.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, EVFM, AEZS, HOLI

Retrieved on: 
Tuesday, December 19, 2023
Advertising, Fraud, Aeterna, Sale, Security (finance)

If you are a Codorus shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Codorus shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Shareholder Alert: Ademi LLP investigates whether Evofem Biosciences, Inc. has obtained a Fair Price in its transaction with Aditxt

Retrieved on: 
Tuesday, December 12, 2023
OTCQB

MILWAUKEE, Dec. 12, 2023 /PRNewswire/ -- Ademi LLP is investigating Evofem (OTCQB: EVFM) for possible breaches of fiduciary duty and other violations of law in its transaction with Aditxt.

Key Points: 
  • MILWAUKEE, Dec. 12, 2023 /PRNewswire/ -- Ademi LLP is investigating Evofem (OTCQB: EVFM) for possible breaches of fiduciary duty and other violations of law in its transaction with Aditxt.
  • In the transaction, the holders of Evofem's common stock will exchange their shares for an aggregate of 610,000 shares of Aditxt common stock.
  • The transaction agreement unreasonably limits competing transactions for Evofem by imposing a significant penalty if Evofem accepts a competing bid.
  • If you own Evofem common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/evofem-biosciences-inc .

Evofem Biosciences Announces Financial Results for the Third Quarter of 2023

Retrieved on: 
Tuesday, November 14, 2023
Sale, DTC, Research, Employment, Citric acid, OTCQB, Food, Samsung Galaxy Note 10, Fourth, Fourth Amendment, Constitutional right, Exercise, Abbreviated New Drug Application, Weather, FDA, Marketing, Note, Lactic acid, Birth, Security, Private law, Growth, Fourth Amendment Protection Act, Contra, Cryptocurrency, Rare-earth element, Pharmaceutical industry, Security (finance), Generic drug, Lactic acid/citric acid/potassium bitartrate

SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced financial results for the third quarter and nine months ended September 30, 2023. Highlights include:

Key Points: 
  • — Reduced loss from operations by 81% vs. Q3 2022 —
    SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced financial results for the third quarter and nine months ended September 30, 2023.
  • Highlights include:
    $5.1 million in net product sales of Phexxi® (lactic acid, citric acid and potassium bitartrate) for the third quarter of 2023 and $13.4 million year-to-date 2023.
  • Third quarter total operating expenses were $8.7 million for 2023, a decrease of 65% as compared with the same period last year.
  • Narrowed loss from operations by 81% in the third quarter of 2023 as compared with the prior year quarter.

Evofem Biosciences Announces Preliminary Results for the Third Quarter of 2023

Retrieved on: 
Tuesday, October 24, 2023
FDA, Food, Security, Note, Regulation of tobacco by the U.S. Food and Drug Administration, Citric acid, OTCQB, Lactic acid, Lactic acid/citric acid/potassium bitartrate, Growth, Marketing, File, New Drug Application, Fourth, Abbreviated New Drug Application, Fourth Amendment, Constitutional right, Video game, Pharmaceutical industry

SAN DIEGO, Oct. 24, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFMD) ("Evofem") today announced preliminary results for the third quarter of 2023, including sequential growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate) and the positive impact of ongoing cost containment initiatives.

Key Points: 
  • Phexxi net product sales expected to be $5.0 to $5.2 million for the third quarter of 2023.
  • Selling and marketing expenses were more than 75% lower and total operating expenses were more than 65% lower in the third quarter of 2023 than the third quarter of 2022.
  • Reduced loss from operations by more than 80% in the third quarter of 2023 as compared to the third quarter of 2022.
  • The Company expects to report full unaudited results for the three- and nine- months ended September 30, 2023, in mid-November.